Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure

Assesses the efficacy of one course of rituximab (two 1-g doses) compared to an alternative tumor necrosis factor-α (TNFα) blocker in rheumatoid arthritis patients who had experienced one previous TNFα blocker failure (eg, etanercept, adalimumab, or infliximab). Source: National Library of New Zeala...

Full description

Saved in:
Bibliographic Details
Published inBiologics Vol. 6; no. default; pp. 191 - 199
Main Authors Kekow, Joern, Mueller-Ladner, Ulf, Schulze-Koops, Henrik
Format Journal Article
LanguageEnglish
Published New Zealand Taylor & Francis Ltd 01.01.2012
Dove Medical Press
Subjects
Confidence intervals
Immunotherapy
Monoclonal antibodies
Original Research
Peptides
Rheumatism
Rheumatoid arthritis
Rituximab
Treatment
Tumor necrosis factor-TNF
anti-cyclic citrullinated peptide antibodies
rheumatoid arthritis
rheumatoid factor
rituximab
Online AccessGet full text

Cover

More Information
Summary:Assesses the efficacy of one course of rituximab (two 1-g doses) compared to an alternative tumor necrosis factor-α (TNFα) blocker in rheumatoid arthritis patients who had experienced one previous TNFα blocker failure (eg, etanercept, adalimumab, or infliximab). Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.
Bibliography:Archived by the National Library of New Zealand
Includes references
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1177-5475
1177-5491
1177-5491
1177-5475
DOI:10.2147/BTT.S32244